102: Immunotherapy in the Management of HCC-Immunotherapy in Management of HCC (102)

Video Transcription

Video Summary

In this webinar on immunotherapy for hepatocellular carcinoma (HCC), Dr. Roshna Shroff discusses advancements and current treatments. Over the past decade, immunotherapy has dramatically changed HCC treatment options, improving patient outcomes with advanced HCC. Key treatments include combinations like atezolizumab with bevacizumab and tremolimumab with durvalumab, which have shown promising results in increasing survival while maintaining safety. Candidates for these treatments are generally those with Child-Pugh A cirrhosis due to their better liver function. Dr. Shroff emphasizes a multidisciplinary approach involving GI specialists, oncologists, and radiologists for comprehensive patient management. Current research focuses on combining local regional and systemic therapies, pre-transplant immunotherapy use, and the quest for effective molecular biomarkers. While promising, complexities in understanding the tumor microenvironment make biomarker-based treatment decisions challenging, underscoring the importance of continued research and collaboration in the field.

Keywords

immunotherapy

hepatocellular carcinoma

atezolizumab

tremolimumab

multidisciplinary approach

biomarkers